We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+66.84%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$807M
Cap. Flow
+$35.6M
Cap. Flow %
1.56%
Top 10 Hldgs %
52.32%
Holding
69
New
7
Increased
11
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$37.5M
2
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$36.1M
3
AMRN
Amarin Corp
AMRN
+$32.7M
4
RNAM
Avidity Biosciences
RNAM
+$32.3M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$23.8M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$65.9M
2
IMMU
Immunomedics Inc
IMMU
+$53.9M
3
RCUS icon
Arcus Biosciences
RCUS
+$27M
4
SAGE
Sage Therapeutics
SAGE
+$15.9M
5
AXSM icon
Axsome Therapeutics
AXSM
+$8.82M

Sector Composition

Rank Sector Weight
1 Healthcare 85.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
51
Kiniksa Pharmaceuticals
KNSA
$5.8B
$7.4M 0.33%
290,577
– –
CBAY
52
DELISTED
Cymabay Therapeutics
CBAY
$6.98M 0.31%
2,000,000
– –
MIRM icon
53
Mirum Pharmaceuticals
MIRM
$6.46B
$6.17M 0.27%
317,000
– –
TARA icon
54
Protara Therapeutics
TARA
$220M
$6.13M 0.27%
209,227
+9,660
+5% +$299K
ICPT
55
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$6.04M 0.27%
+126,000
New +$9.73M
ZYME icon
56
Zymeworks
ZYME
$1.61B
$5.95M 0.26%
165,000
+140,000
+560% +$5.16M
IOVA icon
57
Iovance Biotherapeutics
IOVA
$1.82B
$5.49M 0.24%
+200,000
New +$6.58M
SYRE icon
58
Spyre Therapeutics
SYRE
$8.54B
$5.09M 0.22%
+22,000
New +$4.19M
SLDB icon
59
Solid Biosciences
SLDB
$794M
$4.49M 0.2%
102,125
– –
MIST icon
60
Milestone Pharmaceuticals
MIST
$138M
$4.17M 0.18%
1,102,194
– –
LJPC
61
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.79M 0.17%
890,700
– –
LSACU
62
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$2.99M 0.13%
300,000
– –
BLPH
63
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$1.24M 0.05%
98,809
– –
CLRB icon
64
Cellectar Biosciences
CLRB
$20.5M
$1.18M 0.05%
3,067
– –
ZGNX
65
DELISTED
Zogenix, Inc.
ZGNX
$737K 0.03%
27,300
-147,700
-84% -$4.07M
AXSM icon
66
Axsome Therapeutics
AXSM
$11.2B
– –
-150,000
Closed -$8.82M
REGN icon
67
Regeneron Pharmaceuticals
REGN
$78.5B
– –
-135,000
Closed -$65.9M
VXX icon
68
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
$154M
– –
-1,172
Closed -$3.47M
JJT
69
PUT
DELISTED
iPath Series B Bloomberg Tin Subindex Total ReturnSM ETN
JJT
– –
-300,000
Closed -$13.9M
1 2
3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2020 Portfolio in Review

As of Q2 2020, Boxer Capital held 69 positions worth $2.27B, up 55% from $1.47B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Boxer Capital's Q2 2020 filing shows 7 new, 11 increased, 6 reduced and 4 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 607,000 shares worth $36.3M. The largest sale was Regeneron Pharmaceuticals, an estimated $65.9M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier.

  • Boxer Capital's largest Q2 2020 buy was Principia Biopharma Inc. Common Stock: 607,000 shares worth $36.3M.
  • Boxer Capital added most to Direxion Daily S&P Biotech Bear 3X ETF in Q2 2020, an estimated $36.1M increase.
  • Boxer Capital's biggest Q2 2020 reduction was Immunomedics Inc, cutting an estimated $53.9M.
  • Boxer Capital fully exited Regeneron Pharmaceuticals in Q2 2020, selling an estimated $65.9M.
  • Boxer Capital's ten largest holdings make up 52% of its $2.27B portfolio in Q2 2020.
  • Boxer Capital opened 7 new positions and closed 4 in Q2 2020.
  • Boxer Capital's portfolio value rose 55% quarter-over-quarter to $2.27B.

Based on Boxer Capital's 13F filing for Q2 2020, filed 14 Aug 2020.